Evaluation of Statin Prescribing Practices and Predictors of Statin Underutilization in Persons With HIV

Michelle C Cottino1,2, Caitlin E Kulig1,3, Jin S Suh1,4

  • 1St. Joseph's University Medical Center, Paterson, NJ.

Insights

Persons with HIV (PWH) often don't receive statin therapy despite higher cardiovascular disease (CVD) risk. Tobacco use predicts underutilization, highlighting gaps in CVD prevention for PWH.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • Persons with HIV (PWH) face elevated cardiovascular disease (CVD) risks.
  • PWH are less likely to receive statin therapy compared to the general population.
  • Understanding statin prescribing patterns in HIV clinics is crucial for CVD prevention.

Purpose of the Study:

  • To examine statin prescribing practices in an outpatient HIV clinic.
  • To identify factors associated with statin underutilization among PWH.
  • To inform targeted CVD prevention strategies for this population.

Main Methods:

  • Retrospective chart review of 606 PWH aged 40-79.
  • Evaluation of statin eligibility, prescribing patterns, and therapy appropriateness.
  • Logistic regression analysis to identify predictors of statin underutilization.

Main Results:

  • Statin therapy was indicated for 60% of patients (362/606).
  • 28.2% of indicated patients did not receive statin therapy.
  • Tobacco use (P=0.0023) predicted underutilization, while clinical atherosclerotic CVD and hypertension increased prescribing odds.

Conclusions:

  • Significant statin underutilization exists in PWH, particularly smokers and those without established CVD risk factors.
  • Identifying predictors of underutilization is key to addressing gaps in cardiovascular care for PWH.
  • Enhanced CVD prevention efforts are necessary for PWH to mitigate risks effectively.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
738
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.1K
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
90
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
178
Factors Influencing Drug Absorption: Disease States and Pharmacology01:25

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
621